- Home
- ALNY vs ITUB Comparison
ALNY vs ITUB Comparison
Compare ALNY & ITUB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- ITUB
- Stock Information
- Founded
- ALNY 2002
- ITUB 1924
- Country
- ALNY United States
- ITUB Brazil
- Employees
- ALNY N/A
- ITUB N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- ITUB Major Banks
- Sector
- ALNY Health Care
- ITUB Finance
- Exchange
- ALNY Nasdaq
- ITUB Nasdaq
- Market Cap
- ALNY 60.7B
- ITUB 71.6B
- IPO Year
- ALNY 2004
- ITUB N/A
- Fundamental
- Price
- ALNY $463.36
- ITUB $7.32
- Analyst Decision
- ALNY Strong Buy
- ITUB Buy
- Analyst Count
- ALNY 27
- ITUB 3
- Target Price
- ALNY $466.46
- ITUB $6.27
- AVG Volume (30 Days)
- ALNY 1.0M
- ITUB 25.2M
- Earning Date
- ALNY 10-30-2025
- ITUB 11-04-2025
- Dividend Yield
- ALNY N/A
- ITUB 5.78%
- EPS Growth
- ALNY N/A
- ITUB 17.30
- EPS
- ALNY N/A
- ITUB 0.73
- Revenue
- ALNY $2,461,963,000.00
- ITUB $24,734,987,511.00
- Revenue This Year
- ALNY $60.04
- ITUB $39.38
- Revenue Next Year
- ALNY $40.69
- ITUB $6.66
- P/E Ratio
- ALNY N/A
- ITUB $10.01
- Revenue Growth
- ALNY 5.01
- ITUB 1.84
- 52 Week Low
- ALNY $205.87
- ITUB $4.42
- 52 Week High
- ALNY $495.55
- ITUB $7.45
- Technical
- Relative Strength Index (RSI)
- ALNY 49.33
- ITUB 62.24
- Support Level
- ALNY $456.90
- ITUB $7.11
- Resistance Level
- ALNY $485.36
- ITUB $7.39
- Average True Range (ATR)
- ALNY 16.80
- ITUB 0.11
- MACD
- ALNY -1.23
- ITUB 0.04
- Stochastic Oscillator
- ALNY 33.70
- ITUB 88.33
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About ITUB Itau Unibanco Banco Holding SA (Each repstg 500 Preferred shares)
Itaú Unibanco is the largest privately held bank in Brazil, the result of the 2008 merger between Banco Itaú and Unibanco. In addition to Brazil, the bank has significant operations in Chile, Colombia, Argentina, Uruguay, and Paraguay. Itaú's commercial and consumer loans account for 35% and 43% of the bank's total loans, respectively, while foreign loans account for 22% of its portfolio. The bank also operates the fifth-largest insurer in Brazil and is the second-largest asset manager in the country, giving it broad reach over the Brazilian financial system.